You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 7, 2024

~ Buy the RELISTOR (methylnaltrexone bromide) Drug Profile, 2024 PDF Report in the Report Store ~

RELISTOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Relistor, and when can generic versions of Relistor launch?

Relistor is a drug marketed by Salix Pharms and Salix and is included in two NDAs. There are fourteen patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and thirty-seven patent family members in thirty-eight countries.

The generic ingredient in RELISTOR is methylnaltrexone bromide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methylnaltrexone bromide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Relistor

A generic version of RELISTOR was approved as methylnaltrexone bromide by ACTAVIS LLC on August 26th, 2024.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RELISTOR?
  • What are the global sales for RELISTOR?
  • What is Average Wholesale Price for RELISTOR?
Drug patent expirations by year for RELISTOR
Drug Prices for RELISTOR

See drug prices for RELISTOR

Recent Clinical Trials for RELISTOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Alabama at BirminghamN/A
Odense University HospitalPhase 2/Phase 3
Asbjørn Mohr DrewesPhase 2/Phase 3

See all RELISTOR clinical trials

Pharmacology for RELISTOR
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Paragraph IV (Patent) Challenges for RELISTOR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RELISTOR Tablets methylnaltrexone bromide 150 mg 208271 1 2016-09-06
RELISTOR Injection methylnaltrexone bromide 8 mg/0.4 mL, Single Dose Prefilled Syringe 021964 1 2015-09-08
RELISTOR Injection methylnaltrexone bromide 12 mg/0.6 mL, Single Dose Vial 021964 1 2015-07-22

US Patents and Regulatory Information for RELISTOR

RELISTOR is protected by fourteen US patents.

Patents protecting RELISTOR

Oral formulations and lipophilic salts of methylnaltrexone
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Oral formulations and lipophilic salts of methylnaltrexone
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Stable pharmaceutical formulations of methylnaltrexone
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF OPIOID-INDUCED CONSTIPATION

Peripheral opioid receptor antagonists and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF OPIOID-INDUCED CONSTIPATION

Peripheral opioid receptor antagonists and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF OPIOID-INDUCED CONSTIPATION

Oral formulations and lipophilic salts of methylnaltrexone
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Stable methylnaltrexone preparation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Peripheral opioid receptor antagonists and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF OPIOID-INDUCED CONSTIPATION

Oral formulations and lipophilic salts of methylnal trexone
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Peripheral opioid receptor antagonists and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF OPIOID-INDUCED CONSTIPATION

Oral formulations and lipophilic salts of methylnaltrexone
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Peripheral opioid receptor antagonists and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF OPIOID-INDUCED CONSTIPATION

Stable pharmaceutical formulations of methylnaltrexone
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Peripheral opioid receptor antagonists and uses thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF OPIOID-INDUCED CONSTIPATION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Salix RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Salix RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Salix RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RELISTOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 ⤷  Sign Up ⤷  Sign Up
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 ⤷  Sign Up ⤷  Sign Up
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-003 Sep 27, 2010 ⤷  Sign Up ⤷  Sign Up
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for RELISTOR

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Bausch Health Ireland Limited Relistor methylnaltrexone bromide EMEA/H/C/000870
Treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.
Authorised no no no 2008-07-01
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for RELISTOR

When does loss-of-exclusivity occur for RELISTOR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 3520
Patent: ANTAGONISTAS DE RECEPTORES OPIOIDES PERIFERICOS Y USOS DE LOS MISMOS
Estimated Expiration: ⤷  Sign Up

Patent: 0491
Patent: FORMULACIONES ORALES Y SALES LIPOFILICAS DE METILNALTREXONA
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 09298500
Patent: Peripheral opioid receptor antagonists and uses thereof
Estimated Expiration: ⤷  Sign Up

Patent: 11224275
Patent: Oral formulations and lipophilic salts of methylnaltrexone
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 0919539
Patent: antagonistas de receptor de opioide periférico e empregos dos mesmos
Estimated Expiration: ⤷  Sign Up

Patent: 2012022873
Patent: formulações orais e sais lipofílicos de metilnaltrexona
Estimated Expiration: ⤷  Sign Up

Patent: 2020013665
Patent: seringas pré-carregadas compreendendo composição líquida de metilnaltrexona com baixo teor de tungstênio e os usos da dita composição na preparação de seringas pré-carregadas, medicamentos e kits para o tratamento de constipação induzida por opioides
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 76881
Patent: ANTAGONISTES DE RECEPTEURS OPIOIDES PERIPHERIQUES, ET LEURS UTILISATIONS (PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 89798
Patent: FORMULATIONS ORALES ET SELS LIPOPHILES DE METHYLNALTREXONE (ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 12002192
Patent: Sal de metilnaltrexona cuyo anión es un excipiente anfifílico; composición farmacéutica para administración oral que comprende esta sal y un excipiente anfifílico; método de preparación de la composición farmaceutica; método para reducir efectos secundarios de la terapia opioide; producto; y paquete multidía.
Estimated Expiration: ⤷  Sign Up

China

Patent: 2307874
Patent: Peripheral opioid receptor antagonists and uses thereof
Estimated Expiration: ⤷  Sign Up

Patent: 2918039
Patent: Oral formulations and lipophilic salts of methylnaltrexone
Estimated Expiration: ⤷  Sign Up

Patent: 3833634
Patent: Peripheral opioid receptor antagonists and uses thereof
Estimated Expiration: ⤷  Sign Up

Patent: 5399673
Patent: Peripheral Opioid Receptor Antagonists And Uses Thereof
Estimated Expiration: ⤷  Sign Up

Patent: 7308125
Patent: 甲基纳曲酮的口服制剂和亲脂盐 (Oral formulations and lipophilic salts of methylnaltrexone)
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 30134
Patent: Formulación orales y sales lipofílicas de metilnaltrexona
Estimated Expiration: ⤷  Sign Up

Costa Rica

Patent: 120476
Patent: FORMULACIONES ORALES Y SALES LIPOFÍLICAS DE METILNALTREXONA
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 12012208
Patent: FORMULACIONES ORALES Y SALES LIPOFÍLICAS DE METILNALTREXONA
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 9096
Patent: ТВЕРДАЯ ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ, СОДЕРЖАЩАЯ МЕТИЛНАЛТРЕКСОН (SOLID DOSAGE FORM FOR ORAL ADMINISTRATION COMPRISING METHYLNALTREXONE)
Estimated Expiration: ⤷  Sign Up

Patent: 1270741
Patent: ПЕРОРАЛЬНЫЕ КОМПОЗИЦИИ И ЛИПОФИЛЬНЫЕ СОЛИ МЕТИЛНАЛТРЕКСОНА
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 56119
Patent: ANTAGONISTES DE RÉCEPTEURS OPIOÏDES PÉRIPHÉRIQUES ET LEURS UTILISATIONS (PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 71357
Patent: Formulations orales et sels lipophiles de la méthylnaltrexone (Oral formulations and lipophilic salts of methylnaltrexone)
Estimated Expiration: ⤷  Sign Up

Patent: 86997
Patent: Antagonistes de récepteur opioïde périphérique et leurs utilisations (Peripheral opioid receptor antagonists and uses thereof)
Estimated Expiration: ⤷  Sign Up

Patent: 78472
Patent: FORMULATIONS ORALES DE LA MÉTHYLNALTREXONE (ORAL FORMULATIONS OF METHYLNALTREXONE)
Estimated Expiration: ⤷  Sign Up

Patent: 08322
Patent: SERINGUE CONTENANT DU BROMURE DE NMTX (SYRINGE CONTAINING NMTX BROMIDE)
Estimated Expiration: ⤷  Sign Up

Patent: 71151
Patent: SERINGUE CONTENANT DU BROMURE DE NMTX (SYRINGE CONTAINING NMTX BROMIDE)
Estimated Expiration: ⤷  Sign Up

Georgia, Republic of

Patent: 01606550
Patent: ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
Estimated Expiration: ⤷  Sign Up

Guatemala

Patent: 1200247
Patent: FORMULACIONES ORALES Y SALES LIPOFÍLICAS DE METILNALTREXONA
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 99442
Patent: 周邊的鴉片受體拮抗藥及其用途 (PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 45673
Patent: 甲基納曲酮的口服製劑和親脂鹽 (ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 33133
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 1865
Patent: אנטאגוניסטים לקולטן חיצוני של אופיואיד ושימושיהם (Peripheral opioid receptor antagonists and uses thereof)
Estimated Expiration: ⤷  Sign Up

Patent: 1452
Patent: הרכבים למתן דרך הפה ומלחים ליפופילים של מתילנלטרקסון (Oral formulations and lipophilic salts of methylnaltrexone)
Estimated Expiration: ⤷  Sign Up

Patent: 9507
Patent: אנטאגוניסטים לקולטן חיצוני של אופיואיד ושימושיהם (Peripheral opioid receptor antagonists and uses thereof)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 19773
Estimated Expiration: ⤷  Sign Up

Patent: 43409
Estimated Expiration: ⤷  Sign Up

Patent: 29955
Estimated Expiration: ⤷  Sign Up

Patent: 47368
Estimated Expiration: ⤷  Sign Up

Patent: 47713
Estimated Expiration: ⤷  Sign Up

Patent: 11190259
Patent: ORAL FORMULATION AND LIPOPHILIC SALT OF METHYLNALTREXONE
Estimated Expiration: ⤷  Sign Up

Patent: 12504635
Estimated Expiration: ⤷  Sign Up

Patent: 15129144
Patent: 末梢オピオイド受容体アンタゴニストおよびその使用 (PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 16029054
Patent: メチルナルトレキソンの経口製剤および親油性塩 (ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE)
Estimated Expiration: ⤷  Sign Up

Patent: 17101053
Patent: 末梢オピオイド受容体アンタゴニストおよびその使用 (PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 17206553
Patent: メチルナルトレキソンの経口製剤および親油性塩 (ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE)
Estimated Expiration: ⤷  Sign Up

Patent: 19031536
Patent: 末梢オピオイド受容体アンタゴニストおよびその使用 (PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 19034958
Patent: メチルナルトレキソンの経口製剤および親油性塩 (ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE)
Estimated Expiration: ⤷  Sign Up

Patent: 20196733
Patent: 末梢オピオイド受容体アンタゴニストおよびその使用 (PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF)
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 0727
Patent: ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 9145
Patent: FORMULACIONES ORALES Y SALES LIPOFILICAS DE METILNALTREXONA. (ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE.)
Estimated Expiration: ⤷  Sign Up

Patent: 8805
Patent: FORMULACIONES ORALES Y SALES LIPOFÍLICAS EN METILNALTREXONA. (ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE.)
Estimated Expiration: ⤷  Sign Up

Patent: 11003400
Patent: ANTAGONISTAS DE RECEPTORES DE OPIACEOS PERIFERICOS Y USO DE LOS MISMOS. (PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF.)
Estimated Expiration: ⤷  Sign Up

Patent: 12009125
Patent: FORMULACIONES ORALES Y SALES LIPOFILICAS DE METILNALTREXONA. (ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE.)
Estimated Expiration: ⤷  Sign Up

Patent: 18015087
Patent: ANTAGONISTAS DE RECEPTORES DE OPIACEOS PERIFERICOS Y USOS DE LOS MISMOS. (PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF.)
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 146
Patent: FORMULATIONS ORALLES ET SELS LIPOPHILES DE METHYLNALTREXONE
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 1859
Patent: PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 1595
Patent: Oral formulations and lipophilic salts of methylnaltrexone
Estimated Expiration: ⤷  Sign Up

Patent: 2667
Patent: Peripheral opioid receptor antagonists and uses thereof
Estimated Expiration: ⤷  Sign Up

Patent: 9972
Patent: Peripheral opioid receptor antagonists and uses thereof
Estimated Expiration: ⤷  Sign Up

Patent: 2826
Patent: Oral formulations and lipophilic salts of methylnaltrexone
Estimated Expiration: ⤷  Sign Up

Patent: 3564
Patent: Oral formulations and lipophilic salts of methylnaltrexone
Estimated Expiration: ⤷  Sign Up

Patent: 0085
Patent: Peripheral opioid receptor antagonists and uses thereof
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 130063
Patent: FORMULACIONES ORALES Y SALES LIPOFILICAS DE METILNALTREXONA
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 71357
Estimated Expiration: ⤷  Sign Up

Patent: 78472
Estimated Expiration: ⤷  Sign Up

Patent: 08322
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 08322
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 11117335
Patent: АНГОНИСТЫ ПЕРИФЕРИЧЕСКИХ РЕЦЕПТОРОВ ОПИОИДОВ И ИХ ПРИМЕНЕНИЯ
Estimated Expiration: ⤷  Sign Up

Patent: 13157119
Patent: АНТАГОНИСТЫ ПЕРИФЕРИЧЕСКИХ РЕЦЕПТОРОВ ОПИОИДОВ И ИХ ПРИМЕНЕНИЯ
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 3133
Patent: ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
Estimated Expiration: ⤷  Sign Up

Patent: 4393
Patent: PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 201501821R
Patent: ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
Estimated Expiration: ⤷  Sign Up

Patent: 201606618P
Patent: ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1808498
Patent: ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1566675
Estimated Expiration: ⤷  Sign Up

Patent: 1913102
Estimated Expiration: ⤷  Sign Up

Patent: 1982482
Estimated Expiration: ⤷  Sign Up

Patent: 110060967
Patent: PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 130010900
Patent: ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
Estimated Expiration: ⤷  Sign Up

Patent: 140091071
Patent: PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF
Estimated Expiration: ⤷  Sign Up

Patent: 180118260
Patent: 메틸날트렉손의 경구 제형 및 친유성 염 (ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 23926
Estimated Expiration: ⤷  Sign Up

Patent: 14884
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 89293
Estimated Expiration: ⤷  Sign Up

Patent: 05814
Estimated Expiration: ⤷  Sign Up

Patent: 1141479
Patent: Oral formulations and lipophilic salts of methylnaltrexone
Estimated Expiration: ⤷  Sign Up

Patent: 1622724
Patent: Oral formulations and lipophilic salts of METHYLNALTREXONE
Estimated Expiration: ⤷  Sign Up

Tunisia

Patent: 12000392
Patent: ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 1717
Patent: СКЛАД ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕННЯ І ЛІПОФІЛЬНІ СОЛІ МЕТИЛНАЛТРЕКСОНУ
Estimated Expiration: ⤷  Sign Up

Patent: 3856
Patent: ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ МЕТИЛНАЛТРЕКСОНУ ТА НАТРІЮ ДОДЕЦИЛСУЛЬФАТУ ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕННЯ
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RELISTOR around the world.

Country Patent Number Title Estimated Expiration
Spain 2528631 ⤷  Sign Up
European Patent Office 2371357 Formulations orales et sels lipophiles de la méthylnaltrexone (Oral formulations and lipophilic salts of methylnaltrexone) ⤷  Sign Up
Mexico 349145 FORMULACIONES ORALES Y SALES LIPOFILICAS DE METILNALTREXONA. (ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE.) ⤷  Sign Up
Australia 2011224275 Oral formulations and lipophilic salts of methylnaltrexone ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.